Results 1 to 10 of about 5,807 (256)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Frontiers in Immunology, 2023
Bispecific antibodies have attracted more attention in recent years for the treatment of tumors, in which most of them target CD3, which mediates the killing of tumor cells by T cells.
Xinghui Xiao, Xinghui Xiao, Ying Cheng, Ying Cheng, Xiaodong Zheng, Xiaodong Zheng, Yuhang Fang, Yuhang Fang, Yu Zhang, Yu Zhang, Rui Sun, Rui Sun, Zhigang Tian, Zhigang Tian, Zhigang Tian, Haoyu Sun, Haoyu Sun   +16 more
doaj   +3 more sources

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy [PDF]

The Journal of Clinical Investigation
Alyssa M. Duffy, Anshika Goenka, Maryam I. Azeem, Azmain Taz, Sayalee V. Potdar, Sara A. Scott, Ellen Marin, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Vikas A. Gupta, Sagar Lonial, Ajay K. Nooka, Madhav V. Dhodapkar, Kavita M. Dhodapkar   +14 more
doaj   +4 more sources

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice [PDF]

Nature Communications
Tumor infiltrating T cells (TIL) are key players in the anti-tumor immune response. However, chronic exposure to tumor-derived antigens drives the differentiation into ‘exhausted’ TILs.
Xuhao Zhang, Yu Gao, Wenbo Hu, Yong Liang, Xiaozhe Yin, Xiangjun Shi, Hongjia Li, Huiping Liao, Jingya Guo, Xiaohong Yu, Mingzhao Zhu, Hua Peng, Wenyan Wang, Yang-Xin Fu   +13 more
doaj   +2 more sources

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy [PDF]

Signal Transduction and Targeted Therapy
T cell engager (TCE) immunotherapies have revolutionized the landscape of cancer treatment; however, their efficacy remains limited by the inaccessibility of intracellular tumor antigens.
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu   +7 more
doaj   +2 more sources

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +2 more sources

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin

OncoImmunology, 2023
Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment.
Daniel Snell, Tea Gunde, Stefan Warmuth, Bithi Chatterjee, Matthias Brock, Christian Hess, Maria Johansson, Alexandre Simonin, Fabio Mario Spiga, Christopher Weinert, Niels Kirk, Nicole Bassler, Lucia Campos Carrascosa, Naomi Flückiger, Robin Heiz, Sandro Wagen, Noreen Giezendanner, Alessandra Alberti, Yasemin Yaman, Dana Mahler, Dania Diem, Peter Lichtlen, David Urech   +22 more
doaj   +3 more sources

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Biomedicines, 2020
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling ...
Zong Sheng Guo, Michael T. Lotze, Zhi Zhu, Walter J. Storkus, Xiao-Tong Song   +4 more
doaj   +3 more sources

The landscape of bispecific T cell engager in cancer treatment [PDF]

Biomarker Research, 2021
T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu   +4 more
doaj   +3 more sources

Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy [PDF]

Journal for ImmunoTherapy of Cancer
Background Bispecific T cell engagers have demonstrated promising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multiple challenges including T cell anergy resulting from ...
Qi Sun, Ying Wang, Qin Liu, Baorui Liu, Jie Shao, Fangcen Liu, Xiaotong Chen, Jingyi Guo, Mengzhu Li, Tianran Chen, Yuxiang Li, Jiayao Yan, Jiaqi Nie   +12 more
doaj   +2 more sources

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma.
Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw   +5 more
openaire   +3 more sources